La enfermedad inflamatoria intestinal y los riesgos de enfermedad cardiovascular
Nuñez, P. ; García Mateo, S. ; Quera, R. ; Gomollón, F. (Universidad de Zaragoza)
Resumen: La enfermedad inflamatoria intestinal (EII), comprende tanto a la colitis ulcerosa como a la enfermedad de Crohn, entidades consideradas enfermedades inmunomediadas, sistémicas y de curso crónico que conllevan a menudo el desarrollo de manifestaciones extraintestinales. A pesar de que el estudio de las comorbilidades haya sido desarrollado tradicionalmente en contexto de otras enfermedades inflamatorias sistémicas, este concepto está emergiendo también en la EII. Multitud de patologías han sido vinculadas a la EII, entre las que destaca la enfermedad cardiovascular, la primera causa de muerte en los países desarrollados. Los pacientes con EII están expuestos a un mayor riesgo de entidades tales como arterosclerosis precoz e infarto de miocardio, o trombosis venosas y tromboembolismo pulmonar. El objetivo de esta revisión es hacer una aproximación a la fisiopatología de las diferentes manifestaciones de la enfermedad cardiovascular en los pacientes con EII y de cómo prevenirlas.
Inflammatory bowel disease (IBD) includes both ulcerative colitis and Crohn's disease, which are well recognised as chronic systemic and immune-mediated conditions that frequently involve extraintestinal manifestations. Although comorbidities have long been the subject of research in other chronic inflammatory diseases, this concept is also emerging in IBD. Many pathologies have been linked to IBD, including cardiovascular disease, which is the main cause of death in developed countries. IBD patients are at increased risk of conditions such as early atherosclerosis and myocardial infarction or venous thrombosis and pulmonary thromboembolism. The aim of this review is to make an approximation of the physiopathology of the different manifestations of cardiovascular disease in patients with IBD and how to prevent them.
Idioma: Español
DOI: 10.1016/j.gastrohep.2020.09.002
Año: 2021
Publicado en: Gastroenterologia y Hepatologia 44, 3 (2021), 236-242
ISSN: 0210-5705
Factor impacto JCR: 5.867 (2021)
Categ. JCR: GASTROENTEROLOGY & HEPATOLOGY rank: 29 / 92 = 0.315 (2021) - Q2 - T1
Factor impacto CITESCORE: 1.1 - Medicine (Q3)
Factor impacto SCIMAGO: 0.28 - Hepatology (Q3) - Gastroenterology (Q3)
Tipo y forma: Review (PostPrint)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material.
Exportado de SIDERAL (2023-05-18-15:16:44)
Visitas y descargas
Inflammatory bowel disease (IBD) includes both ulcerative colitis and Crohn's disease, which are well recognised as chronic systemic and immune-mediated conditions that frequently involve extraintestinal manifestations. Although comorbidities have long been the subject of research in other chronic inflammatory diseases, this concept is also emerging in IBD. Many pathologies have been linked to IBD, including cardiovascular disease, which is the main cause of death in developed countries. IBD patients are at increased risk of conditions such as early atherosclerosis and myocardial infarction or venous thrombosis and pulmonary thromboembolism. The aim of this review is to make an approximation of the physiopathology of the different manifestations of cardiovascular disease in patients with IBD and how to prevent them.
Idioma: Español
DOI: 10.1016/j.gastrohep.2020.09.002
Año: 2021
Publicado en: Gastroenterologia y Hepatologia 44, 3 (2021), 236-242
ISSN: 0210-5705
Factor impacto JCR: 5.867 (2021)
Categ. JCR: GASTROENTEROLOGY & HEPATOLOGY rank: 29 / 92 = 0.315 (2021) - Q2 - T1
Factor impacto CITESCORE: 1.1 - Medicine (Q3)
Factor impacto SCIMAGO: 0.28 - Hepatology (Q3) - Gastroenterology (Q3)
Tipo y forma: Review (PostPrint)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material. Exportado de SIDERAL (2023-05-18-15:16:44)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles
Record created 2021-11-15, last modified 2023-05-19